subject: The Florida Hospital Cancer Institute Becomes a Member of the Radiation Therapy Oncology Group [print this page] The Florida Hospital Cancer Institute Becomes a Member of the Radiation Therapy Oncology Group
The Florida Hospital Cancer Institute Becomes a Member of the Radiation Therapy Oncology Group
For 40 years RTOG has conducted studies designed to improve the survival and quality of life of cancer patients. RTOG continues to define new national standards of care for cancer patients. The Florida Hospital Cancer Institute is proud to be affiliated with the RTOG and to continue to be at the forefront of clinical trials in order to provide our patients with the best chance of beating their disease.
The Radiation Therapy Oncology Group (RTOG) was established in 1967 as a cooperative effort of physicians, physicists, biologists, and biostatisticians to pursue clinical investigations designed to increase survival and improve the quality of life of patients with cancer.
Over 300 academic and community-based facilities in the United States, Canada and internationally participate in RTOG clinical trials, including nearly 90 percent of all NCI-designated comprehensive and clinical cancer centers.
Since its inception, RTOG has opened more than 460 protocols, enrolled over 75,000 patients to its studies, and published more than 700 papers reporting the results of its findings. RTOG maintains a roster of 40 active studies devoted to the group's primary disease sites: central nervous system, head & neck, lung, gastrointestinal (esophagus, stomach, pancreas, anal canal, and rectum), genitourinary (bladder and prostate), breast, and cervix.
RTOG's Mission
* Improve the survival outcome and quality of life ofdults with cancer through the conduct of high-qualityclinical trials.
* Evaluate new forms of radiotherapy delivery, including stereotactic radiotherapy, brachytherapy, 3-dimensional conformal radiotherapy (3-DCRT), and intensitymodulated adiotherapy (IMRT) in the context of clinical research.
* Test new systemic therapies in conjunction with radiotherapy, including chemotherapeutic drugs, hormonal strategies, biologic agents, and new classes of cytostatic, cytotoxic, and targeted therapies.
* Employ translational research strategies to identify patient subgroups at risk for failure with existing treatments and identify new approaches for these patients.
welcome to Insurances.net (https://www.insurances.net)
